Literature DB >> 19852727

Mechanisms of the epithelial-mesenchymal transition by TGF-beta.

Michael K Wendt1, Tressa M Allington, William P Schiemann.   

Abstract

The formation of epithelial cell barriers results from the defined spatiotemporal differentiation of stem cells into a specialized and polarized epithelium, a process termed mesenchymal-epithelial transition. The reverse process, epithelial-mesenchymal transition (EMT), is a metastable process that enables polarized epithelial cells to acquire a motile fibroblastoid phenotype. Physiological EMT also plays an essential role in promoting tissue healing, remodeling or repair in response to a variety of pathological insults. On the other hand, pathophysiological EMT is a critical step in mediating the acquisition of metastatic phenotypes by localized carcinomas. Although metastasis clearly is the most lethal aspect of cancer, our knowledge of the molecular events that govern its development, including those underlying EMT, remain relatively undefined. Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that oversees and directs all aspects of cell development, differentiation and homeostasis, as well as suppresses their uncontrolled proliferation and transformation. Quite dichotomously, tumorigenesis subverts the tumor suppressing function of TGF-beta, and in doing so, converts TGF-beta to a tumor promoter that stimulates pathophysiological EMT and metastasis. It therefore stands to reason that determining how TGF-beta induces EMT in developing neoplasms will enable science and medicine to produce novel pharmacological agents capable of preventing its ability to do so, thereby improving the clinical course of cancer patients. Here we review the cellular, molecular and microenvironmental mechanisms used by TGF-beta to mediate its stimulation of EMT in normal and malignant cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19852727      PMCID: PMC2858056          DOI: 10.2217/fon.09.90

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  236 in total

1.  The integrin-coupled signaling adaptor p130Cas suppresses Smad3 function in transforming growth factor-beta signaling.

Authors:  Wook Kim; Yong Seok Kang; Jin Soo Kim; Nah-Young Shin; Steven K Hanks; Woo Keun Song
Journal:  Mol Biol Cell       Date:  2008-03-05       Impact factor: 4.138

2.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.

Authors:  Sun-Mi Park; Arti B Gaur; Ernst Lengyel; Marcus E Peter
Journal:  Genes Dev       Date:  2008-04-01       Impact factor: 11.361

Review 3.  Transitions between epithelial and mesenchymal states in development and disease.

Authors:  Buzz Baum; Jeffrey Settleman; Margaret P Quinlan
Journal:  Semin Cell Dev Biol       Date:  2008-02-09       Impact factor: 7.727

4.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.

Authors:  Shuomin Zhu; Hailong Wu; Fangting Wu; Daotai Nie; Shijie Sheng; Yin-Yuan Mo
Journal:  Cell Res       Date:  2008-03       Impact factor: 25.617

5.  An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.

Authors:  Ittai Ben-Porath; Matthew W Thomson; Vincent J Carey; Ruping Ge; George W Bell; Aviv Regev; Robert A Weinberg
Journal:  Nat Genet       Date:  2008-05       Impact factor: 38.330

6.  An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.

Authors:  Jeong-Seok Nam; Masaki Terabe; Mizuko Mamura; Mi-Jin Kang; Helen Chae; Christina Stuelten; Ethan Kohn; Binwu Tang; Helen Sabzevari; Miriam R Anver; Scott Lawrence; David Danielpour; Scott Lonning; Jay A Berzofsky; Lalage M Wakefield
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

7.  Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta.

Authors:  Amy J Galliher-Beckley; William P Schiemann
Journal:  Carcinogenesis       Date:  2008-01-03       Impact factor: 4.944

8.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

9.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.

Authors:  Philip A Gregory; Andrew G Bert; Emily L Paterson; Simon C Barry; Anna Tsykin; Gelareh Farshid; Mathew A Vadas; Yeesim Khew-Goodall; Gregory J Goodall
Journal:  Nat Cell Biol       Date:  2008-03-30       Impact factor: 28.824

10.  Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression.

Authors:  Jason R Neil; William P Schiemann
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

View more
  130 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  Role of DeltaNp63gamma in epithelial to mesenchymal transition.

Authors:  Jaime Lindsay; Simon S McDade; Adam Pickard; Karen D McCloskey; Dennis J McCance
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

3.  Chitosan scaffold enhances growth factor release in wound healing in von Willebrand disease.

Authors:  Mercy Halleluyah Periayah; Ahmad Sukari Halim; Arman Zaharil Mat Saad; Nik Soriani Yaacob; Abdul Rahim Hussein; Faraizah Abdul Karim; Ahmad Hazri Abdul Rashid; Zanariah Ujang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway.

Authors:  Wei Li; Jiguang Ma; Qingyong Ma; Bin Li; Liang Han; Jiangbo Liu; Qinhong Xu; Wanxing Duan; Shuo Yu; Fengfei Wang; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

5.  Chemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers.

Authors:  Yong-Hun Lee; William P Schiemann
Journal:  Breast Cancer Manag       Date:  2014

Review 6.  The role of cytokines in breast cancer development and progression.

Authors:  Marcela Esquivel-Velázquez; Pedro Ostoa-Saloma; Margarita Isabel Palacios-Arreola; Karen E Nava-Castro; Julieta Ivonne Castro; Jorge Morales-Montor
Journal:  J Interferon Cytokine Res       Date:  2014-07-28       Impact factor: 2.607

7.  Critical role of miR-10b in transforming growth factor-β1-induced epithelial-mesenchymal transition in breast cancer.

Authors:  Xu Han; Sun Yan; Zhang Weijie; Wang Feng; Wang Liuxing; Li Mengquan; Fan Qingxia
Journal:  Cancer Gene Ther       Date:  2014-01-24       Impact factor: 5.987

Review 8.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

9.  SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis.

Authors:  Petra Simic; Eric O Williams; Eric L Bell; Jing Jing Gong; Michael Bonkowski; Leonard Guarente
Journal:  Cell Rep       Date:  2013-04-11       Impact factor: 9.423

10.  ZEB1 promotes the progression and metastasis of cervical squamous cell carcinoma via the promotion of epithelial-mesenchymal transition.

Authors:  Yihui Ma; Xiangyu Zheng; Jun Zhou; Ying Zhang; Kuisheng Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.